Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
基本信息
- 批准号:10477625
- 负责人:
- 金额:$ 38.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-13 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAlloantigenAllograftingAnaerobic BacteriaAnti-Inflammatory AgentsAntibioticsAtherosclerosisAutomobile DrivingB-LymphocytesBacteriaBacteroidesBifidobacteriumBile AcidsBloodCardiacCell NucleusCellsCharacteristicsChronicCommunitiesComplexCongestive Heart FailureDataDendritic CellsDesulfovibrioDiagnosisDiagnosticDrug ExposureEndothelial CellsEndotoxinsEpithelialEquilibriumFermentationFiberFibrosisFunctional disorderGoalsGraft RejectionGraft SurvivalHealthHeart TransplantationImmuneImmune responseImmunityImmunologicsImmunosuppressionImmunosuppressive AgentsInflammationInflammatoryInflammatory ResponseInjuryInterventionIntestinesKnowledgeLactobacillusLamininLeadLigandsLymphaticMediatingMesenteryMetabolicMetagenomicsMissionMolecularMucous MembraneMusMyeloid CellsNational Institute of Allergy and Infectious DiseaseOutcomePathologicPermeabilityPharmaceutical PreparationsPlayPreventiveQuality of lifeRegulatory T-LymphocyteReticular CellRoleSerumSmall Nuclear RNAStructureSurvival RateT-LymphocyteTherapeuticTherapeutic InterventionTransplantationVascular DiseasesVolatile Fatty AcidsWorkacylcarnitinebasecell typeclinically relevantcytokinedysbiosisfatty acid metabolismfecal microbiotagraft failuregut microbiomeheart allograftimmunoregulationimprovedinterstitialintestinal barrierintestinal epitheliumintestinal injuryisoimmunityliver injurylymph nodesmacrophagemicrobialmicrobial communitymicrobiomemortalitymouse modelnovelpermissivenesspost-transplantpregnantresponsesystemic inflammatory responsetooltranscriptometranscriptome sequencingtransplant modeltrimethyloxamine
项目摘要
PROJECT SUMMARY
Though the one-year survival rate in cardiac transplantation has reached 90-95%, the mortality rate beyond the
first year has not changed in the last two decades. Immune-mediated damage remains the primary cause of
long-term graft failure. Findings from our and other studies provide the rationale for investigating the gut
microbiome as a determinant of post-transplantation outcomes and as a potential tool to induce immune
modulation to improve long-term graft outcomes. The goal of this study is to determine the mechanisms by
which the gut microbiome impacts allograft outcome. We postulate that the disrupted metabolic activities of the
gut microbiome lead to inflammatory responses and intestinal injury via cell-type specific responses in the
intestinal cells network, which subsequently modulate alloimmunity and ultimately chronic cardiac graft
outcomes. We will take advantage of our clinically-relevant cardiac transplant murine model of chronic rejection
with well-characterized alloresponses, induced by pro- or anti-inflammatory bacteria, to determine the
alterations in the microbial metabolic activities in Aim 1, then to identify local intestinal barrier changes and the
underlying intestinal cell-type specific responses in Aim 2, and finally to characterize systemic alloresponses
and graft survival in Aim 3, in order to obtain a holistic understanding of the precise mechanisms of
microbiome-driven chronic graft outcomes. The proposed work will identify novel and critical microbiome-based
targets for diagnostic application and therapeutic intervention, and discern the complex and bidirectional
dialogue between the microbiome and alloimmunity to promote transplant immunologic quiescence and long-
term cardiac graft survival.
项目摘要
尽管心脏移植的一年生存率已达到90-95%,但死亡率超过
在过去的二十年中,第一年没有改变。免疫介导的损伤仍然是
长期移植失败。我们和其他研究的发现提供了研究肠道的基本原理
微生物组是移植后结果的决定因素,也是诱导免疫的潜在工具
调节以改善长期移植结果。这项研究的目的是确定
肠道微生物组会影响同种异体移植结果。我们假设,破坏了代谢活动的破坏
肠道微生物组导致通过细胞类型的特异性反应导致炎症反应和肠道损伤
肠道细胞网络,随后调节同种免疫力并最终调节慢性心脏移植
结果。我们将利用与临床相关的心脏移植鼠模型的慢性排斥模型
由促疾病或抗炎细菌诱导的充分表征的同种酶,以确定
AIM 1中微生物代谢活动的改变,然后确定局部肠道屏障的变化和
AIM 2中的基本肠细胞类型特异性反应,最后表征全身性同种酶
AIM 3中的嫁接生存,以便获得对精确机制的整体理解
微生物组驱动的慢性移植结果。拟议的工作将确定基于新颖和关键的微生物组
诊断应用和治疗干预的目标,并辨别复合物和双向
微生物组与同种免疫性之间的对话,以促进移植免疫静止和长期
术语心脏移植生存。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan S Bromberg其他文献
Jonathan S Bromberg的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan S Bromberg', 18)}}的其他基金
Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
- 批准号:
10621899 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
- 批准号:
10662321 - 财政年份:2020
- 资助金额:
$ 38.63万 - 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
- 批准号:
10224026 - 财政年份:2020
- 资助金额:
$ 38.63万 - 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
- 批准号:
10024598 - 财政年份:2020
- 资助金额:
$ 38.63万 - 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
- 批准号:
10431927 - 财政年份:2020
- 资助金额:
$ 38.63万 - 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
- 批准号:
10439697 - 财政年份:2019
- 资助金额:
$ 38.63万 - 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
- 批准号:
10202721 - 财政年份:2019
- 资助金额:
$ 38.63万 - 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
- 批准号:
9975884 - 财政年份:2019
- 资助金额:
$ 38.63万 - 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
- 批准号:
9795098 - 财政年份:2019
- 资助金额:
$ 38.63万 - 项目类别:
U Maryland Mid-Atlantic APOLLO Research Network Omic and Clinical Center
马里兰大学大西洋中部阿波罗研究网络组学和临床中心
- 批准号:
10729890 - 财政年份:2017
- 资助金额:
$ 38.63万 - 项目类别:
相似国自然基金
菌根真菌介导的同种密度制约对亚热带森林群落物种共存的影响
- 批准号:32371600
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
B7H4-LILRB4信号调控B细胞代谢重编程机制在同种抗体产生及防治AMR中的作用
- 批准号:82371792
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:32200491
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
抗骨髓瘤的新型同种异体嵌合抗原受体T(CAR T)细胞疗法研发
- 批准号:82270210
- 批准年份:2022
- 资助金额:68 万元
- 项目类别:面上项目
利用HERV-K(HML-2)多态性探讨不同种族群体的遗传多样性和疾病易感性差异
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Peptide-dependent mobilization of CD8 regulatory cells in cardiac transplantation
心脏移植中 CD8 调节细胞的肽依赖性动员
- 批准号:
10585628 - 财政年份:2023
- 资助金额:
$ 38.63万 - 项目类别:
Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
- 批准号:
10621899 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
HLA Immunogenetics and kidney allograft outcomes
HLA 免疫遗传学和肾同种异体移植结果
- 批准号:
10566338 - 财政年份:2022
- 资助金额:
$ 38.63万 - 项目类别:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
评估天然和 3D 打印同种异体移植物中不同人类细胞类型的免疫原性和抗原性
- 批准号:
10353416 - 财政年份:2021
- 资助金额:
$ 38.63万 - 项目类别: